PDS Biotechnology Corp — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
PDS Biotechnology announced a strategic refocus on August 11, 2026, discontinuing internal investment in PDS0101 and halting the VERSATILE-003 Phase 3 trial, while prioritizing PDS0301 (tumor-targeted IL-12 immunocytokine). Concurrent with this pivot, the company reported Q2 2026 net loss of $9.8 million on $5.6 million cash (down from $26.7 million at year-end 2025), with negative working capital of $5.3 million and stockholders' equity now negative at $(3.6) million. PDS0301 showed strong clinical data in mCRC (77.8% ORR vs. 35% control; 80% 24-month survival vs. 35% control).
Why this rating
Strategic pivot with strong clinical upside but severe cash burn and negative equity threaten near-term viability. Cash runway critically short relative to $60M market cap.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.